Showing results (231-240 of 244) with videos related to
Sort By:
Pageof 25
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.Nature Medicine|March 13, 2026
A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trialAurélie Ploquin, Rosemarie D Mason, LaSonji A Holman, et al.Science (New York, N.Y.)|December 14, 2023
HIV vaccines induce CD8+ T cells with low antigen receptor sensitivityStephen A Migueles, Danielle M Nettere, Noah V Gavil, et al.Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.Pageof 25